180 Life Sciences’ (ATNF) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of 180 Life Sciences (NASDAQ:ATNF) in a research note released on Saturday,Weiss Ratings reports.

180 Life Sciences Stock Performance

NASDAQ:ATNF opened at $1.10 on Friday. The stock’s 50 day moving average price is $0.99 and its 200 day moving average price is $1.64. 180 Life Sciences has a 52-week low of $0.66 and a 52-week high of $17.75.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in 180 Life Sciences stock. Anson Funds Management LP purchased a new position in shares of 180 Life Sciences Corp. (NASDAQ:ATNF) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 225,271 shares of the company’s stock, valued at approximately $410,000. Anson Funds Management LP owned about 7.08% of 180 Life Sciences as of its most recent SEC filing. 4.07% of the stock is owned by institutional investors.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.